Silver Book Fact

Treatment with zoledronic acid over a 3-year period reduced risk of vertebral fracture by around 70% and risk of hip fracture by 41%, and increased bone mineral density (BMD) by 5% to 6%.

Black D, Delmas P, Eastell R, et al. Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. NEJM. 2007; 356(18): 1809-22. http://content.nejm.org/cgi/content/abstract/356/18/1809

Reference

Title
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Publication
NEJM
Publication Date
2007
Authors
Black D, Delmas P, Eastell R, et al
Volume & Issue
Volume 356, Issue 18
Pages
1809-22
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • A systematic review of osteoporosis therapies found good evidence that many are effective in preventing fractures, but concluded that the data are insufficient to determine if any one therapy is…  
  • Tools to Prevent Secondary Osteoporosis Fractures are Not Being Used
     
  • Reducing secondary bone fractures can reduce medicare spending
    Reducing 5-20 percent of “secondary” bone fractures in 2015 could have reduced Medicare FFS spending by $310 million to $1.2 billion over a follow-up period that lasted up to 2 to…  
  • Hip fracture prevention in at-risk, postmenopausal women saves $333 million annually.  
  • Raloxifene, a selective estrogen receptor modulator (SERM) has been shown to increase vertebral bone mineral density (BMD) by 2% to 3% after 3 years.